Immune checkpoint inhibitors, including those that target the programmed cell death 1 and programmed cell death ligand 1 (PD-1 and PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) pathways, are revolutionizing cancer therapy [44, 45]. Here, PDCD1 is linked to cancer.